ZD 2574
Latest Information Update: 07 Apr 1999
At a glance
- Originator AstraZeneca
- Class Heart failure therapies
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease; Heart failure
Most Recent Events
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed
- 14 Sep 1998 Discontinued-Preclinical for Chronic obstructive pulmonary disease in United Kingdom (Unknown route)
- 14 Sep 1998 Discontinued-Preclinical for Heart failure in United Kingdom (Unknown route)